Mayo Clinic Study: Stacking Warning Signs on Pancreatic Cysts Sharply Raises Cancer Risk

Pancreatic cancer kills fast because doctors find it late. A new Mayo Clinic study out of Rochester, Minnesota, gives physicians something they haven't had before: an actual number to put on the risk that a pancreatic cyst turns into cancer.

The study, led by gastroenterologist Shounak Majumder, MD, followed 230 patients whose pancreatic cysts showed worrisome or high-risk features. It was published in the journal Gastroenterology, with results also detailed by Mayo Clinic News Network on August 20, 2026.

One worrisome feature meant roughly a 2% chance of developing pancreatic cancer or advanced precancerous changes within three years. Two worrisome features pushed that to 4%. Three or more features drove the risk up to about 18%, according to Mayo Clinic's own reporting on the study.

MedPage Today, citing the same research, rounded that top figure to nearly 20% and noted something important: worrisome traits showed up in more than 90% of the 185 patients who had any concerning features at all, while true high-risk traits were rare. In plain terms, most patients in this study weren't dealing with the scariest imaging findings. They were dealing with a pile-up of moderate red flags, and that pile-up is what drove the risk higher.

How the study actually worked

This wasn't a records review that only looked backward at patients who already had surgery, which is how a lot of prior pancreatic cyst research has been done. Mayo Clinic enrolled patients up front and tracked them forward, regardless of whether they chose surgery or watchful monitoring, according to Medical Xpress and Newswise, both of which carried Mayo's own release on the findings.

Of the 230 participants, 32 had surgery within three months of enrolling. The other 198 went into surveillance. Among those under surveillance, 185 had cysts with worrisome features and 13 had high-risk features, per the Mayo Clinic and Newswise accounts.

Overall survival during the study period was 95%, MedPage Today reported. That's good news for patients, but it also means the number of actual cancer cases was small. Majumder acknowledged this limits how far the findings can be pushed. The study could show that risk climbs with more warning signs, but it couldn't pin down which specific combination of traits matters most.

What this means for patients weighing surgery

Pancreatic cysts aren't rare. They show up in up to 18% of the general population, usually found by accident on a scan ordered for something else entirely, according to MedPage Today. Most never become cancer. But surgery on the pancreas is serious, invasive, and carries its own risks, which is exactly why doctors need better tools to decide who actually needs it.

"Sometimes, we are unable to reliably determine whether a cyst will become pancreatic cancer or not," Majumder said, according to Mayo Clinic News Network. "That uncertainty creates a lot of anxiety for some patients undergoing surveillance, and some will opt for surgery."

Patients anxious about an ambiguous cyst sometimes choose surgery they may not have needed, just to make the uncertainty go away. A number like "18% risk with three-plus worrisome features" versus "2% risk with just one" gives doctors something concrete to put in front of a patient instead of a shrug.

Majumder was direct about the limits of his own work. "Obviously, this is a small study done at a single center," he told MedPage Today, "but if this starts getting confirmed and validated in broader settings, then that could become something that's more practice changing." He added that it won't overhaul current guidelines on its own: "I don't think this study by itself is going to completely change our practice, but it's going to inform practice a little bit."

A 230-patient study from one hospital system is a data point, not a new clinical standard. The existing guidelines for managing pancreatic cysts with worrisome or high-risk features remain in place. What Majumder's team has added is a sharper way to stratify risk within those guidelines, based on how many red flags stack up on a single patient's scan.

Pancreatic cancer is already the third-leading cause of cancer death in the U.S. and is projected to become the second-leading cause by 2030, according to MedPage Today. The next step, per Majumder, is getting these numbers tested and confirmed at other institutions. Until that happens, doctors treating patients with multiple worrisome cyst features now have a rough percentage to work with, rather than just clinical instinct.